MEETINGS

Using Population Pharmacokinetics to Support the Development of Clinically Relevant Specifications for Extended Formulations
Using Population Pharmacokinetics to Support the Development of Clinically Relevant Specifications for Extended Formulations

A workshop co-sponsored by the American Association of Pharmaceutical Scientists and the Controlled Release Society

Saturday, November 13, 2010

Morial Convention Center, New Orleans, Louisiana, U.S.A.
To be held immediately prior to the FIP Pharmaceutical Sciences World Congress 2010 in association with the AAPS Annual Meeting - http://www.pswc2010.org/

The Quality by Design (QbD) paradigm is ushering in new approaches for achieving a streamlined, knowledge-based process for generating products optimized to meet patient needs. Development of a Quality Target Product Profile (QTPP) can help maximize the likelihood of achieving the therapeutic objective by linking critical product quality attributes (CQAs) to the desired in vivo performance. In this workshop, we will discuss developing a QTPP through PK/PD modeling and simulation approaches that will enable linking CQAs to clinical outcome. Through the integration of population PK/PD models established on the basis of clinical trial data, this integrative approach could ensure the establishment of in vitro drug dissolution/release methods that link to the desired in vivo product performance, thereby providing dissolution/release criteria that are consistently informative and clinically relevant.

WHO SHOULD ATTEND: bench and clinical scientists involved in the development or regulation of modified release formulations and the optimization of dosing strategies.

REGISTRATION

Preregistration ends November 3, 2010. After that date, you must register onsite in New Orleans.

Regular
On or before September 10 - $995

Late/Onsite
After September 11 or onsite - $1095

3 Easy Ways to Register

Online: www.pswc2010.org
Mail or Fax: Visit www.pswc2010.org to download the registration form

Mail to:
2010 FIP PSWC/AAPS Annual Meeting & Exposition
PO Box 590
Frederick, MD 21705 U.S.A.

Meeting Registration/Questions
Phone: +1.301.694.5234
Toll-Free (U.S.A., Canada, Mexico): 1.866.229.2386

ACCOMMODATIONS

The Hilton New Orleans Riverside will serve as the headquarters hotel for this meeting. Rooms have also been reserved at several New Orleans hotels. You must reserve your room by October 22, 2010, to guarantee the meeting rate. Call the PSWC Housing Bureau at 1.800.724.0858 or visit www.pswc2010.org to make your reservation.

Duration (min)

Begin

End

Speaker

Title

 

8:30

8:45

Marilyn Martinez
FDA Center for Vet Medicine, U.S.A.

Introduction and objectives

0:40

8:45

9:25

Terrance Ocheltree
Food and Drug Administration, U.S.A.

Quality by Design: impact on drug development and its global applications

0:40

9:25

10:05

Raafat Fahmy
Food and Drug Administration, U.S.A.

Design space and product specifications: a risk assessment approach

0:40

10:05

10:45

Arzu Selen
Food and Drug Administration, U.S.A.

Quality Product Target Profile: Integrating product in vivo performance in a patient population with product design.

0:15

10:45

11:00

Break

0:40

11:00

11:40

Kevin Johnson
Intellipharm LLC, U.S.A. and John Crison, Bristol-Myers Squibb, U.S.A.

Development of oral drug delivery platforms based upon patient GI characteristics

0:20

11:40

12:00

Audience Discussion

1:00

12:00

13:00

Lunch

0:40

11:00

11:40

Adrian Dunne
Johnson & Johnson and University of College Dublin, Ireland

A nonlinear mixed effects IVIVC model for multi-release drug delivery systems

0:40

13:40

14:20

Roger Jelliffe
University of Southern California, U.S.A.

The use of therapeutic drug monitoring to identify the relationships between optimized dosing strategies (input function) versus patient characteristics (covariates): Using this information to develop a target for in vivo product release characteristics

0:40

14:20

15:00

William Jusko,
University at Buffalo, U.S.A.

The development of mechanistic population pharmacokinetic models to support the development of targeted release characteristics from modified release dosage forms

0:20

15:00

15:20

Break

0:40

15:20

16:00

Jeffrey Barrett
Children’s Hospital of Philadelphia, U.S.A.

The use of modeling and simulation to target dosing strategies and predict optimal in vivo product release characteristics in a pediatric population.

0:40

16:00

16:40

Maria Cruanes,
Merck & Co., U.S.A.

Integrating patient in vivo performance characteristics into product design and specifications: a manufacturing perspective. 

0:20

16:40

17:00

Round Table Discussion and Audience Participation

0:10

16:00

16:10

Marilyn Martinez
FDA Center for Vet Medicine, U.S.A.

Closing comments and adjourn